DOCSLIB.ORG

Analysis of Bio-Molecules for System Level Understanding of Alzheimer’S Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Analysis of Bio-Molecules for System Level Understanding of Alzheimer’S Disease ANALYSIS OF BIO-MOLECULES FOR SYSTEM LEVEL UNDERSTANDING OF ALZHEIMER’S DISEASE By PRIYA PRADAYANI PANIGRAHI A THESIS SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOINFORMATICS JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY WAKNAGHAT OCTOBER, 2014 ACKNOWLEDGEMENTS God gives blessings to us so we can give glory to him. I'm blessed and I thank God for everything in my life. I deem it my privilege and honour to place and record my gratitude and indebtedness to the following without whose support, guidance, and concern I would not have been able to complete my Ph. D thesis. I feel privileged to express my deep sense of reverence and gratitude to my revered mentor, Dr. Tiratha Raj Singh, for his support, immaculate guidance, constructive criticism, constant encouragement and providing requisite facilities to carry on my research which otherwise would have remained incomplete. His nurturing and caring concern has been a stimulus which I will always cherish. I also appreciate his untiring efforts during the entire tenure of my research work and patience during writing of this thesis. I have no words to express my gratitude for everything he has contributed in my Ph. D and without his blessings it was surely impossible for me to finish my work. I thank him from bottom of my heart. I emphatically express my loyal and venerable thanks to Prof. Shiban Kishen Kak (Vice Chancellor, JUIT), Brig. (Retd.) Balbir Singh (Director, JUIT), Prof. T. S.Lamba (Dean, JUIT) and Dr. Y. Medury (Ex-COO, Jaypee Education System) for providing opportunity to pursue a Doctorate Degree, teaching assistantship and advanced lab infrastructure to accomplish this scientific venture of my life. I gratefully acknowledge the help rendered by Prof. R. S. Chauhan (Dean, BT and HOD, Dept. of BT& BI) for his encouragement, timely help and cooperation throughout my research work. It gives me immense pleasure to express my gratitude to Chauhan Sir for his ever smiling disposition coming to my rescue in solving my problems and suggestions which helped me in maintaining my confidence. I also feel indebted to my all time advisor, Mr. Sudipta Ku. Das (Lect. in dept. of Zoology, P.S.College, gaisilat, Odissa), Dr. Ragini Raj Singh (Assist.Prof. Dept. of Physics and Material Science, JUIT), and Dr. Anupriya Kaur (Assist. Prof., Dept. of Humanities and Social Science, JUIT) for their valuable advice, unconditional support and guidance. This document would have remained an infant had it not received its necessary ‘diet’ in the form of comments, suggestions etc. by Dr. C. Rout, Dr. J. Ramana, Dr. Udayabanu M., Dr. Pradeep Kumar Naik, and Dr.Hemant Sood. I am short of words in expressing my thanks to them, for their innovative ideas that shaped this document. I wish to convey my sincere thanks to all the faculty members of Department of Biotechnology and Bioinformatics, for their help and guidance at the various stages of this study. I am also thankful to all the members of technical and non-technical staff of the department for their assistance and valuable contributions. I am fortunate to have friends who have always stood beside me. I extend my heartfelt thanks to Jatin Sir, Varun Sir, Krishna Sir, Bharti Ma’am, Archit, Nikhil, Manika, Ashwani, Tarun, Ankita, Tamanna, Pawan, Dikshita and Deepika for their sustained support and ever needed cooperation. I also thank Asha, Pallavi, Nidhi, Dibyajyoti, and Yamini for their inspiration throughout my life. It is my pleasure to express my gratitude to all research scholars of the Biotechnology & Bioinformatics Department for keeping me blessed with best wishes. It is worthwhile expressing my gratitude to Dr. Ahmed Moussa, Dr. MoacyrComar Junior, and Mr. Ramit Singla who provided me assistance and valuable contributions. The successful culmination of this thesis could not have been possible without Dr. Kamal Raj Pardasani (Professor, Department of Mathematics, Maulana Azad National Institute of Technology, Bhopal, India) and Dr. Brigitte Vannier (Assistant professor of cell biology, University of Poitiers, Poitiers, France). Their critical review and constructive and insightful comments were very helpful in strengthening this Thesis. The purpose of this acknowledgement will be incomplete if I fail to appreciate the moral support and encouragement rendered by my family and my loving husband, Preetam Biswal (he is also one of my greatest advisor). I would like to express my love to my sweet nephew “Aryaveer Nayak” whose innocence refreshed me during my difficult times. The successful culmination of this thesis could not have been possible without the blessings of my loving parents and Inlaws. Without their help I would have been greatly incapacitated. All may not be mentioned, but no one is forgotten. Priya Pradayani Panigrahi Contents CONTENTS List of Tables I List of Figures II-VI Abbreviations VII-X Abstract 1-4 CHAPTER-1 Introduction 5-41 1.1 Introduction 1.2 Dementia 1.3 Diagnosis of dementia 1.4 Causes of dementia 1.5 Types of dementia and their characteristics 1.5.1 Cortical dementias 1.5.2 Sub-cortical dementias 1.6 History of Alzheimer’s disease 1.7 Alzheimer’s disease 1.7.1 Beta-amyloid plaques 1.7.2 Neurofibrillary tangles 1.8 Aβand its association with TAU 1.9 Symptoms and stages of Alzheimer’s disease 1.9.1 Stage 1 (Mild) 1.9.2 Stage 2 (Moderate) 1.9.3 Stage 3 (Severe) 1.10 Types of Alzheimer’s disease 1.10.1 Early onset Alzheimer’s disease (EOAD) 1.10.2 Late onset Alzheimer’s disease (LOAD) 1.10.3 Familial Alzheimer’s disease (FAD) 1.11 Risk factors for Alzheimer’s disease 1.11.1 Non-genetic risk factors 1.11.1.1 Age 1.11.1.2 Education 1.11.1.3 Concomitant health problems 1.11.2 Genetic risk factors 1.11.2.1 Familial Alzheimer’s disease 1.11.2.2 Sporadic Alzheimer’s disease 1.12 Diagnosis of Alzheimer’s disease 1.13 Important facts of Alzheimer’s disease 1.14 Etiological hypothesis for Alzheimer’s disease 1.14.1 Oxidative stress 1.14.2 Inflammation 1.14.3 Cholinergic hypothesis Jaypee University of Information Technology Contents 1.14.4 Cholesterol metabolism 1.15 Treatment of Alzheimer’s disease 1.16 New remedial advances for treatment of Alzheimer’s disease CHAPTER-2 In silico analysis for functional and evolutionary aspects of 42-62 BACE1 and associated Alzheimer’s releted proteins Abstract 2.1 Introduction 2.2 Materials and methods 2.3 Results and discussion 2.4 Conclusion CHAPTER 3 Enrichment analysis for Alzheimer’s disease associated 63-105 pathways and regulatory patterns with aging and other diseases using microarray gene expression and network data Abstract 3.1 Introduction 3.2 Materials and methods 3.2.1 Data 3.2.2 Data pre-processing 3.2.3 Differential gene expression 3.2.4 Clustering of co-expressed genes 3.2.5 Hypergeometric distribution and association of ranked genes 3.2.6 Topological overlap between co-expressed networks and other associated factors 3.2.7 Prioritization of gene candidates with molecular triangulation 3.2.8 Network motif analysis 3.3 Results and discussion 3.3.1 Differential gene expression, clustering of co- expressed genes 3.3.2 Enrichment analysis through co-expressed networks and ranked list of genes 3.3.3 Novel genes, their variants, transcription factors, and miRNA targets 3.3.4 Brain regions and their pathway mapping 3.3.5 Network motifs and their disease associated annotation 3.4 Conclusion Jaypee University of Information Technology Contents CHAPTER 4 A genome wide association study for all key genes identified 106-126 in our earlier research having direct or indirect impact on the metabolic pathways of Alzheimer’s disease: development of a web resource Abstract 4.1 Introduction 4.2 Materials and methods 4.2.1 Database blueprint 4.2.2 Gene and protein screening process 4.2.3 Compilation of genotype data and their LD, and haplotype analysis 4.3 Results and discussion 4.3.1 Findings 4.3.2 Web outline 4.4 Conclusion CHAPTERS 5 Studies to test the binding of THC-Δ9-tetrahydrocannabinol 127-151 and derivatives on acetylcholine binding protein: a virtual screening and molecular docking study Abstract 5.1 Introduction 5.2 Materials and methods 5.2.1 Molecular docking 5.2.1.1 Substrate selection 5.2.1.2 Rigid docking 5.2.1.3 Induced fit docking (IFD) 5.2.2 Toxicity prediction 5.2.3 Prediction of drug like property 5.2.4 Molecular dynamics simulation 5.3 Results and discussion 5.3.1 Selection of potent lead compound 5.3.2 Molecular docking 5.3.3 Molecular dynamics simulation results 5.3.4 TOPKAT and QIKPROP results 5.4 Conclusion Overall conclusions and future prospects 152-157 Bibliography 158-180 Publications and Presentations 181-183 Jaypee University of Information Technology List of tables LIST OF TABLES Table Title Page No. No. 1.1 Proportional pharmacology of presently accepted drugs 32-33 1.2 Proportional clinical pharmacology of presently available drugs 33-34 2.1 Details of Human and Mus musculus BACE1 Sequences 56 BACE1 Interacting proteins identified through protein-protein 2.2 interaction network. Further functional information compiled 58-61 from literature and other annotations Significant number of genes identified through multifaceted integrative approach. 7 different types of analyses applied on all 3.1 74 data types and number of genes identified for all categories indicated against each one respectively Important putative genes identified through manual screening and computational analyses by applying myriad statistical techniques. Abbreviations used are: PPI Gene Set Enrichment Results (PPI), 3.2 80-85 TTGS, miRNA, and Main KEGG File Results (KEGG).
Load more

Recommended publications
  • Régulation De L'inflammation Par Les Lipides Bioactifs : Interactions Biosynthétiques Et Fonctionnelles Entre Les Endocannabinoïdes Et Les Éicosanoïdes
    Régulation de l'inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Doctorat en microbiologie-immunologie Philosophiæ doctor (Ph. D.) Québec, Canada © Caroline Turcotte, 2019 Régulation de l’inflammation par les lipides bioactifs : interactions biosynthétiques et fonctionnelles entre les endocannabinoïdes et les éicosanoïdes Thèse Caroline Turcotte Sous la direction de : Nicolas Flamand, directeur de recherche Marie-Renée Blanchet, codirectrice de recherche Résumé Les maladies inflammatoires chroniques sont un fardeau de santé important à travers le monde. Les traitements actuellement disponibles soulagent la douleur et l’inflammation, mais leurs effets secondaires rendent leur utilisation à long terme risquée. À la lumière de cette problématique, la communauté scientifique s’intéresse au potentiel d’anti-inflammatoires naturels comme les endocannabinoïdes. Les endocannabinoïdes sont des lipides endogènes qui activent les récepteurs cannabinoïdes (CB1 et CB2). Ils régulent ainsi divers processus physiologiques tels l’appétit, l’adipogénèse et la nociception. Les deux endocannabinoïdes les mieux caractérisés, le 2-AG et l’AEA, peuvent également moduler l’inflammation en activant le récepteur CB2 à la surface des cellules immunitaires. Les souris déficientes pour le récepteur CB2 présentent un phénotype inflammatoire exacerbé, suggérant que ce récepteur est anti-inflammatoire. Cependant, le rôle des endocannabinoïdes dans l’inflammation est beaucoup plus complexe puisqu’ils peuvent être métabolisés en une grande variété de médiateurs lipidiques de l’inflammation. Leur voie de dégradation principale est leur hydrolyse en acide arachidonique (AA), qui sert de précurseur à la biosynthèse d’éicosanoïdes pro-inflammatoires comme le leucotriène B4 et la prostaglandine E2. Ils peuvent également être métabolisés directement par certaines enzymes impliquées dans la synthèse d’éicosanoïdes, pour générer des médiateurs comme les prostaglandines-glycérol (PG-G).
    [Show full text]
  • Regulation of Brain Reward by the Endocannabinoid System: a Critical Review of Behavioral Studies in Animals
    Send Orders for Reprints to [email protected] Current Pharmaceutical Design, 2014, 20, 000-000 1 Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals S. Vlachou2 and G. Panagis1,* 1Laboratory of Behavioral Neuroscience, Department of Psychology, School of Social Sciences, University of Crete, 74100 Rethym- non, Crete, Greece; 2School of Nursing and Human Sciences, Faculty of Science and Health, Dublin City University, Glasnevin, Dub- lin 9, Ireland Abstract: The endocannabinoid system has been implicated in the regulation of a variety of physiological processes, including a crucial involvement in brain reward systems and the regulation of motivational processes. Behavioral studies have shown that cannabinoid re- ward may involve the same brain circuits and similar brain mechanisms with other drugs of abuse, such as nicotine, cocaine, alcohol and heroin, as well as natural rewards, such as food, water and sucrose, although the conditions under which cannabinoids exert their reward- ing effects may be more limited. The purpose of the present review is to briefly describe and evaluate the behavioral and pharmacological research concerning the major components of the endocannabinoid system and reward processes. Special emphasis is placed on data re- ceived from four procedures used to test the effects of the endocannabinoid system on brain reward in animals; namely, the intracranial self-stimulation paradigm, the self-administration procedure, the conditioned place preference procedure and the drug-discrimination pro- cedure. The effects of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonists, antagonists and endocannabinoid modulators in these procedures are examined. Further, the involvement of CB1 and CB2 receptors, as well the fatty acid amid hydrolase (FAAH) en- zyme in reward processes is investigated through presentation of respective genetic ablation studies in mice.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57bl/6J Mice
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Jason Wiebelhaus Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Psychology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/555 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Jason Michael Wiebelhaus, 2013 All Rights Reserved Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain Bundle in C57Bl/6J Mice Dissertation to be submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University By: Jason M. Wiebelhaus Master of Science, Virginia Commonwealth University, 2009 Bachelor of Science, University of WI-Eau Claire, 2006 Co-Directors: Aron H. Lichtman1, Ph.D. and Joseph H. Porter2, Ph.D. 1, 2Professors 1Department of Pharmacology and Toxicology, 2Department of Psychology Virginia Commonwealth University Richmond, VA September, 2013 ii Acknowledgement I owe my thanks to many people who helped me throughout the process of conducting these experiments and writing my dissertation. First and foremost I would like to thank my mentor and dissertation co-director director Aron H. Lichtman for his guidance and patience throughout my years of graduate school at Virginia Commonwealth University. I would also like to thank my committee members Joseph H.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for ADD Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 4 (+)-CEPHARANTHINE 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (+)-TENUIPINE 1 (+)-TETRANDRINE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 2 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-CURINE 1 Chemical Activity Count (-)-DAURISOLINE 1 (-)-DICENTRINE 1 (-)-EMETINE 1 (-)-EPICATECHIN 3 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 2 (-)-EPIGALLOCATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN-GALLATE 2 (-)-EUDESMIN 1 (-)-HYDROXYJASMONIC-ACID 1 (-)-IBOGAMINE 1 (-)-STEPHOLIDINE 1 (-)-TENUIPINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 1-ETHYL-BETA-CARBOLINE 2 1-HYDROXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-METHOXY-2-(3'-PENTENYL)-3,7-DIMETHYLBENZOFURAN 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10,6-HONOKIOL 1
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Epilepsy Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 3 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-HERNANDEZINE 1 (+)-ISOCORYDINE 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 2 (-)-ANABASINE 1 (-)-APOGLAZIOVINE 1 (-)-BETONICINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-DICENTRINE 2 (-)-EPIAFZELECHIN 1 (-)-EPICATECHIN 1 (-)-EPIGALLOCATECHIN-GALLATE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (15:1)-CARDANOL 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 Chemical Activity Count 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 11-HYDROXY-DELTA-8-THC 1 11-HYDROXY-DELTA-9-THC 1 13',II8-BIAPIGENIN 1 13-OXYINGENOL-ESTER 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-EPIMETHUENINE 1 16-HYDROXYINGENOL-ESTER 1 2'-O-GLYCOSYLVITEXIN 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 2 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 1 3,3'-DIMETHYLELLAGIC-ACID 1 3,4-DIMETHOXYTOLUENE 1 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 2 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID 1 3-ACETYLACONITINE 1 3-ACETYLNERBOWDINE 1 3-BETA-HYDROXY-2,3-DIHYDROWITHANOLIDE-F 1 3-HYDROXY-FLAVONE 1 3-N-BUTYL-PHTHALIDE 3 3-O-ACETYLOLEANOLIC-ACID 1 3-OXO-11-ALPHA-HYDROXYOLEAN-12-ENE-30-OIC-ACID
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor
    Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules Yuichi Kobayashi Editor Cutting-Edge Organic Synthesis and Chemical Biology of Bioactive Molecules The Shape of Organic Synthesis to Come Editor Yuichi Kobayashi Department of Biotechnology Tokyo Institute of Technology Yokohama, Japan ISBN 978-981-13-6243-9 ISBN 978-981-13-6244-6 (eBook) https://doi.org/10.1007/978-981-13-6244-6 © Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for GERD / Esophageal Reflux
    Dr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]